Zhang Meng, Xie Wanmu, Xiao Yao, Guo Wei, Wang Yan, Zhang Wenmei, Duan Shengchen, Gao Qian, Zhang Shuai, Zhang Yunxia, Guo Xueran, Yin Ao, Peng Jiafei, Wan Jun, Zhai Zhenguo
Department of Pulmonary and Critical Care Medicine Beijing Anzhen Hospital, Capital Medical University; Beijing Institute of Heart, Lung and Blood Vessel Diseases Beijing China.
Department of Pulmonary and Critical Care Medicine Center of Respiratory Medicine, China‑Japan Friendship Hospital Beijing China.
Pulm Circ. 2023 May 18;13(2):e12241. doi: 10.1002/pul2.12241. eCollection 2023 Apr.
We intended to evaluate the diagnosis and treatment status of pulmonary hypertension (PH) in China and provide the basis for the design of the Chinese PH centers system. A questionnaire survey was conducted by sampling from Chinese Class A tertiary hospitals that have carried out the clinical work of PH, including the composition of PH clinical team, the current application of examinations related to PH diagnosis, the availability of PAH-specific medicine and the implementation of PH-related intervention and surgery. A total of 44 valid questionnaires from 20 provinces were collected in this survey. In the vast majority of centers (83.33%, = 35), pulmonary artery catheterization was routinely performed under X-ray guidance. In 19.05% ( = 8) of centers, pressure measurements were determined at the right time (the end of normal expiration). Only 73.81% ( = 31) centers have carried out acute vasoreactivity testing. Prostacyclin analogues and prostaglandin receptor agonists were just prescribed in 45.45% ( = 20) of the centers. 19 centers (43.18%) were capable of performing balloon pulmonary angioplasty (BPA) and pulmonary endarterectomy (PEA), while 25% ( = 11) were able to perform BPA, PEA, and lung transplantation. There was no significant difference in the diagnosis and treatment of PH between economic regions. The majority of Chinese tertiary hospitals were well equipped with the corresponding personnel, examinations and medicines related to PH, but the standardization and specialization of the management of PH need to be strengthened.
我们旨在评估中国肺动脉高压（PH）的诊断和治疗现状，并为中国PH中心系统的设计提供依据。通过对开展PH临床工作的中国甲级三级医院进行抽样问卷调查，内容包括PH临床团队的组成、目前与PH诊断相关检查的应用情况、PAH特异性药物的可及性以及PH相关干预和手术的实施情况。本次调查共收集到来自20个省份的44份有效问卷。在绝大多数中心（83.33%，n = 35），肺动脉导管插入术在X线引导下常规进行。在19.05%（n = 8）的中心，压力测量在正确时间（正常呼气末）进行。只有73.81%（n = 31）的中心开展了急性血管反应性测试。前列环素类似物和前列腺素受体激动剂仅在45.45%（n = 20）的中心有处方。19个中心（43.18%）能够进行球囊肺血管成形术（BPA）和肺动脉内膜切除术（PEA），而25%（n = 11）能够进行BPA、PEA和肺移植。经济区域之间PH的诊断和治疗没有显著差异。大多数中国三级医院配备了与PH相关的相应人员、检查和药物，但PH管理的标准化和专业化需要加强。
